Sildenafil

Viagra makers are launching a discreet, dissolvable wafer version, Viagra ODF, to replace the iconic blue pill, aiming to address embarrassment and improve patient tolerance. The new form, already available in Canada, is expected to reach the UK within five years, pending regulatory approval.

Daré Bioscience and Strategic Science & Technologies plan a Phase 3 study for Sildenafil Cream, 3.6%, targeting FDA approval for female sexual arousal disorder (FSAD). With no FDA-approved treatments for FSAD, Sildenafil Cream could address a critical unmet need in women's sexual health.

FDA warns supplements marketed as 'all natural' often contain undeclared prescription drugs like sildenafil and tadalafil, posing health risks. These products, often labeled with 'Max,' 'Miracle,' or 'Macho,' are unregulated and can be bought without prescriptions. Experts warn of potential heart disease risks and recommend consulting a trusted doctor before using any supplements.

Medication names are scientifically developed to ensure patient safety, with strict processes including chemical, generic, and brand names. The FDA and international bodies oversee these names to prevent errors and ensure global recognition.

Male birth control options, like Next Life Sciences’ Plan A and Contraline’s ADAM, are nearing market, despite challenges from funding and side effects. These developments occur as the Trump administration may impact drug approvals, though male contraception is seen as separate from abortion debates. Advocates hope male contraceptives can reduce unintended pregnancies and share the responsibility of birth control.

Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.

The EHSAN phase three clinical trial, adhering to the CONSORT statement, evaluates hydralazine's effect on cognitive function in mild to moderate AD patients over 52 weeks, comparing it to a placebo. The trial, involving 424 patients at Adineh Health Clinic, Iran, follows the SPIRIT protocol. Assessments include cognitive evaluations using the ADAS-cog, physical health assessments, and monitoring for adverse events. Inclusion criteria require patients to be 50 years or older, diagnosed with mild to moderate AD, and have a consistent caregiver. Exclusion criteria focus on non-AD primary dementia and other conditions that may confound results. The intervention involves hydralazine or placebo, with randomization stratified by age, sex, and MMSE score. The primary outcome measure is the ADAS-cog, with secondary measures including the Lawton Instrumental Activities of Daily Living Scale, Neuropsychiatric Inventory, and Caregiver Activity Survey. The trial emphasizes strict protocol adherence and safety monitoring through the Data and Safety Monitoring Committee.

Annovis Bio announced financial results for Q3 2024, highlighting FDA approval for Phase 3 studies of buntanetap in early AD, and filing of patents for combination therapies. The company secured $13.6 million in cash and expects to start the 6-month symptomatic study in Q1 2025.

Annovis Bio reported Q3 2024 financial results, including $13.6 million in cash, $4.4 million in Q3 operating expenses, and a net loss of $0.97 per share. The FDA granted clearance for pivotal Phase 3 studies of buntanetap in early Alzheimer's disease, with a 6-month symptomatic study starting Q1 2025. The company raised $4.4 million from ELOC facility and $7.1 million from warrant exercises, and filed three new patents for combination therapies involving buntanetap.

BlueChew offers chewable tablets for erectile dysfunction, with subscriptions ranging from $20–$120/month. While not FDA-approved, its active ingredients are. It provides a free consultation and discreet shipping but does not accept insurance.